Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson's disease target
Oncodesign and Ipsen announced that the two companies have entered into a research collaboration to discover and develop LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's disease and for potential additional uses in other therapeutic areas. Oncodesign and Ipsen will leverage their respective expertise to bring innovative therapeutic solutions to Parkinson patients.
Oncodesign’s Nanocyclix(R) is a proprietary medicinal chemistry technology based on a macrocyclisation process of small chemical molecules that gives access to potent and highly selective small molecule kinase inhibitors with attractive physicochemical and ADME properties. Oncodesign has identified Nanocyclix(R) leads against a broad range of known and unexplored kinases (notably the LRRK2 program) with potential in multiple therapeutic areas. Ipsen will apply its expertise in pharmaceutical R&D and translational sciences while leveraging its network of academic and medical leaders in neurosciences.
Under the terms of the agreement, Ipsen is granted two exclusive options to exclusively license Oncodesign's LRRK2 inhibitor program, notably upon successfully reaching clinical proof of concept, with worldwide development, manufacturing and commercialization rights. Oncodesign is entitled to a technology access fee, funding of the program's research and early development activities, and upon exercise of the license options, opt-in fees and additional development, regulatory and commercial milestone payments potentially totaling EUR115 million (approx. USD149 million) for the development of molecules in two or more indications, and tiered royalties on net sales.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
To-BBB and GSK to collaborate on brain delivery of a biologic product
Heptares partners with cubist to research new medicines targeting GPcrs
Acambis completes enrollment of Phase 3 JE vaccine trials ahead of schedule
Sosei Appoints David Chiswell as Non-Executive Chairman
Infection control certification associated with lower MRSA infection rates
Full-length genome sequencing of Zika from a patient could help unlock the virus’s secrets
Codexis to Establish New R&D Facility in Singapore to Support Expanding Generics Business
AVI BioPharma Presents Antisense Approach to Transplant Acceptance By Regulating Activated Lymphocytes
